Natalizumab, a recently re-approved drug for MS treatment, has been shown to reduce the numbers of CD19+ B cells and CD138+ plasma cells within the CSF [32] which correlated with the reduction of relapse rates as well as of the inflammatory disease activity on MRI. This evidence concerns the gene SDC1 and myeloid sarcoma.